aibioBy aibio.space
Akari's cash lasts about nine months, and its latest filing flags going concern doubt
Akari had $7.7 million at June 30, 2026. Our arithmetic gives about nine months, the company says December 2026, and its lead drug is not yet in the clinic.
AKTX Negative view The company's own cash date falls before its 2027 clinical target, and its latest quarterly report carries going concern language.
Akari Therapeutics calls itself an oncology company developing next generation antibody drug conjugates, or ADCs, built around its own payloads. Its lead drug, AKTX-101, is still preclinical. Our view is that the money matters more than the science right now. The company had $7.7 million of cash, cash equivalents and short-term investments at June 30, 2026 and burns about $2.7 million a quarter on average. Its latest quarterly report says cash lasts into December 2026, and it carries going concern language.
What the company does and where it is
The annual report says the near-term plan is to advance AKTX-101, a Trop-2 targeting ADC that combines the PH1 payload with an antibody, into IND enabling work and clinical readiness. The company has suspended its legacy nomacopan programs and says it intends to seek partners for them. It has no products for sale and no product revenue.
The filings give two dates for the same December 2025 projection. The annual report says AKTX-101 will enter clinical trials by the first quarter of 2027. The quarterly report says by the middle of 2027. The filings do not explain the slip from one date to the other.
Cash and burn
Our runway arithmetic is simple. The company had $7.7 million at June 30, 2026. Its average quarterly operating cash outflow over the last four quarters was $2.7 million. Dividing one by the other gives 2.9 quarters, or about 9 months. The last two quarters averaged $2.8 million, so the runway is a little shorter at that pace. Nine months from June 30 runs into early 2027.
The company's own statement is shorter. In the quarterly report, it says existing cash is sufficient to fund operations into December 2026.
Operating cash outflow has not been steady. It was $2.1 million in the quarter ended September 30, 2025, $3.0 million in December 2025, $2.5 million in March 2026 and $3.1 million in June 2026. The latest quarter is the highest of the last four. We think that matters more than the average.
What management says about its cash
We think the gap has three possible causes. The first is timing. The statement is made as of the report date, which the cover dates to August 13, 2026, so some June cash has already gone. The second is pace. The June quarter outflow of $3.1 million is above the four-quarter average, so management may plan for a higher burn than ours. The third is financing. The quarterly report says the May 2026 private placement raised about $5.2 million net, and that came before June 30. It says funding activities are in progress, but the text we reviewed describes no closed financing after June 30.
The quarterly report also says the statements assume a going concern. It says that 'these factors raise substantial doubt' about that ability for at least one year after issuance. The December 2026 date falls inside that window, so the cash claim and the going concern language point the same way.
Corporate change is not new here. Our March 2025 story reported a delayed annual report while the company finished accounting for a merger. Our November 2024 story said shareholders approved a share issuance for the Peak Bio merger, which the company expected to fix its Nasdaq equity deficiency.
Where the money goes
Research and development expense rose from $0.2 million in the quarter ended September 30, 2025 to $2.1 million in the quarter ended June 30, 2026. The quarterly report says R&D rose by approximately $1.4 million against a year earlier. Most of that sits in ADC preclinical development, mainly payments to outside vendors and consultants. Personnel costs fell.
General and administrative costs were about $2.5 million in the quarter, up by less than $0.1 million. The six-month loss from operations was $20.4 million, including a $12.1 million non-cash impairment on goodwill and intangible assets recorded with the Peak Bio merger. The filing says the impairment test was triggered by the company's market capitalization as of March 31, 2026. We think it is a warning about those assets, even though it does not use cash.
The science so far
AKTX-101 has not been given to a person. The annual report's comparison with Trodelvy, an approved Trop-2 antibody drug conjugate, rests on cell-line and mouse studies run by the company. We think animal results are a weak guide to patient outcomes, and no regulator has reviewed any human data. The steps ahead are finishing IND-enabling work, an FDA clearance, a Phase 1 safety trial and then efficacy trials. No clinical trial has started. The annual report also records that Trodelvy's accelerated approval in urothelial cancer was later withdrawn, which shows how hard it is to turn early activity into an approved Trop-2 drug. The field is crowded, and the company has no clinical result that sets AKTX-101 apart.
The bull case
The bull case starts with progress the filings support. The annual report says that in December 2025 the company announced it had started GMP manufacturing for AKTX-101 and selected WuXi Biologics/XDC as its partner. R&D has risen for three quarters running, which fits a company moving toward an IND. Cash rose from $2.8 million at March 31, 2026 to $7.7 million at June 30, 2026, and the quarterly report refers to a May 2026 private placement. The company also says it believes its payloads may allow ADCs that can be used with checkpoint inhibitors and offer benefits over existing ADCs. Those are company beliefs, not trial results.
The bear case
The bear case is about time, dilution and stage. The company has $7.7 million against an outflow that averaged $2.7 million and reached $3.1 million in June. Its own date is December 2026. Its lead drug is preclinical, it has no product revenue, and it has suspended two legacy programs. The cover page shows 155,758,529,533 ordinary shares outstanding on August 13, 2026. The filing says each ADS represents 80,000 ordinary shares, so the count is about 1.95 million ADSs on our arithmetic. The warrant table lists 6,929,347 warrant ADSs outstanding at June 30, 2026, more than three times that ADS count. About 5.6 million of them (our sum) come from the May 2026 deal, including 1,206,489 prefunded warrants. A $25 million equity line with White Lion Capital is also in place, and a registration statement was declared effective on July 7, 2026. Any use of these would dilute current holders heavily. The public float was about $15.0 million at June 30, 2025, which measures size, not price.
Listing is another pressure. A Nasdaq bid price notice set a May 25, 2026 deadline, and the company regained compliance only after it changed the ADS ratio. The annual report also records earlier notices on the $2.5 million stockholders' equity rule, the latest dated November 24, 2025.
Our view
We think the bear case is stronger for now. The filings describe real work, and manufacturing for the lead drug has started. But the company's own cash date is less than a year away, its filings carry going concern language, and its lead drug has a 2027 clinical target. Any financing that follows will matter more to existing holders than preclinical data in the next year. We would change our view if a disclosed raise funds the company through the first clinical trial. Until then we weigh the lack of human data and the share overhang as heavily as the cash date. This is opinion, not investment advice.
What to watch, and what would change our mind
The next quarterly report, for the cash figure and any change to the December 2026 statement. Whether the going concern language stays. The clinical start for AKTX-101, which the filings give as the first quarter or the middle of 2027. Any new share issuance and the share count on the next cover page. Whether partners are signed for the legacy nomacopan programs. What would change our mind: a financing with a disclosed size that carries the company through the first clinical trial, or a partner that pays for part of the AKTX-101 work.